Intestinal expression of programmed death ligand 1
AssigneeenGene, Inc.
InventorsShauna Marie DAUPHINEE, Connor Daniel Alexander MCCARTHY, Jeremy DUPAUL-CHICOINE, Eric HSU, Ghania CHIKH, Anthony CHEUNG
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions for the amelioration of inflammatory disorders comprising the intestinal expression of programmed death ligand 1.
Claims23
-13. (canceled)
An expression vector comprising a PD-L1 nucleic acid, wherein the sequence of said PD-L1 nucleic acid comprises at least one synonymous substitution compared to SEQ ID NO:
- 2 for detection after administration, and preferably a plurality of synonymous substitutions.
(canceled)
-24. (canceled)
A chitosan derivative nanoparticle comprising an encapsulated expression vector, wherein the expression vector comprises a PD-L1 nucleic acid encoding a human PD-L1 polypeptide for localized intestinal expression of the human PD-L1 polypeptide, wherein the sequence of the PD-L1 nucleic acid comprises a plurality of synonymous substitutions compared to SEQ ID NO 2 for detection after administration.
Dependencies are inferred from the claim text.